Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 4;8(2):101667.
doi: 10.1016/j.jhepr.2025.101667. eCollection 2026 Feb.

Extending the Baveno VII definition of recompensation to autoimmune hepatitis: Considerations regarding treatment timing and response criteria

Benedikt S Hofer  1   2   3   4 , Lukas Burghart  5 , Thomas Reiberger  1   2   3   4 , Albert F Stättermayer  1   4 ; Collaborators
Collaborators, Affiliations

Extending the Baveno VII definition of recompensation to autoimmune hepatitis: Considerations regarding treatment timing and response criteria

Benedikt S Hofer et al. JHEP Rep. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

BSH received travel support from Falk and Ipsen. LB received travel support from Gilead and Ipsen, research grant support from Gilead and speaker honoraria from Ipsen. ST declares no conflict of interest. EH declares no conflict of interest. MM served as a speaker and/or consultant and/or advisory board member for AbbVie, Collective Acumen, Gilead, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. MT has received research grants from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda and Ultragenyx and travel grants from Abbvie, Falk, Gilead, Intercept and Jannsen. He has advised for Abbvie, Albireo, BiomX, Boehringer Ingelheim, Falk Pharma GmbH, Genfit, Gilead, Hightide, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens and Shire and has served as speaker for BMS, Falk, Gilead, Intercept, Madrigal and MSD. He is a co-inventor of patents for the medical use of norUDCA (nor-ursodeoxycholic acid/norucholic acid) filed by the Medical Universities of Graz and Vienna. TR received grant support from AbbVie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from AbbVie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. AFS received speaker honorary from Gilead, Boehringer-Ingelheim, Orphalan, Triogen, consulting/advisory board fees from Abacus Medicine, Gilead, Ipsen, Triogen, and travel support from Gilead, Boehringer-Ingelheim, Roche, MSD, and AbbVie. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

Fig. 1
Fig. 1
Individual outcomes of patients with autoimmune hepatitis-related decompensated cirrhosis stratified by the timepoint of initiation of immunosuppressive therapy. CBR, complete biochemical response; IS, immunosuppression.
See this image and copyright information in PMC

References

    1. Chen Y., Wen H., Li Y., et al. Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy. JHEP Rep. 2025 June 25;0(0) - PMC - PubMed
    1. Hofer B.S., Burghart L., Halilbasic E., et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis. Aliment Pharmacol Ther. 2024 Apr 1;59(8):962–972. - PubMed
    1. Arvaniti P., Rodríguez-Tajes S., Padilla M., et al. Hepatic encephalopathy and MELD-Na predict treatment benefit in autoimmune hepatitis-related decompensated cirrhosis. Clin Gastroenterol Hepatol. 2025 Apr;8(25):S1542–S3565. 00249-6. - PubMed
    1. de Franchis R., Bosch J., Garcia-Tsao G., et al. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022 Apr;76(4):959–974. - PMC - PubMed
    1. Rahim M.N., Miquel R., Heneghan M.A. Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep. 2020 Dec;2(6) - PMC - PubMed

LinkOut - more resources